Thetford Mines, Quebec – TheNewswire - November 3, 2021 – KDA Group Inc. (TSXV:KDA) (“KDA” or the “Corporation”) and its wholly-owned subsidiary, Groupe Technologique KDA Inc. (“Tech KDA”) are pleased to announce that on October 29, 2021, Tech KDA has signed a letter of intent (the “Letter of Intent”) with Oryx Dental Software LLC (“Oryx”) to enter into a partnership agreement with Oryx to market and integrate Tech KDA’s KRx e-prescribing platform for dentists (the “KRx”) into Oryx's dental management software (the “Oryx Software”).

Oryx will integrate the KRx e-prescribing solution for Canadian and U.S. dentists into its Oryx Software, as it is already well established in Canada and the United States. With this Letter of Intent, Tech KDA begins its international expansion in the United States.

Oryx Software is a friendly-user dental management platform that offers patient engagement tools, evidence-based clinical modules, automated risk assessment and diagnosis, as well as billing and advanced reporting. Based on Seattle’s Kois Teaching Center principles, Oryx Software gathers information from a patient’s medical and dental history, as well as from charted exam findings, to generate a comprehensive overview of the patient's dental health.

"We are pleased and proud that Tech KDA can continue its Canadian expansion and enter the international market starting with the United States, a very promising market for our KRx where more than 200,000 dentists1 will be able to access all the advantages and functionalities of the KRx to benefit from increased security and assistance in their daily practice of their dental knowledge. Tech KDA, through its KRx, provides dentists with this essential tool to offer and provide them with a superior and ever more efficient service for the benefit of their patients’ well-being and safety," said Marc Lemieux, Chief Executive Officer of KDA.

ABOUT KDA GROUP

KDA Group is a leading technological innovations and specialized solutions provider in the pharmaceutical market. Today, it is a respected name for quality and expertise among the different stakeholders in the pharmaceutical and medical sector. Its management team is guided by a vision of continuing to lead the way in Quebec while extending operations across Canada and internationally. Additional information on the Corporation is available at www.kdagroup.ca and on SEDAR at www.sedar.com.

REFERENCE

1- French District, Les soins dentaires aux États-Unis (frenchdistrict.com)

- 30 -

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

INFORMATION

Marc Lemieux

Chief Executive Officer

514 622-7370

info@groupekda.ca